H. Lundbeck has been granted a patent for compounds and compositions that can modulate ABHD12, potentially serving as immunotherapies for cancer and infectious diseases. The patent includes a specific compound formula. GlobalData’s report on H. Lundbeck gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on H. Lundbeck, was a key innovation area identified from patents. H. Lundbeck's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11897865B2) discloses a series of compounds represented by Formulas (I) and (II), along with their solvates, N-oxides, stereoisomers, and pharmaceutically acceptable salts. These compounds have various substituents such as halogen, alkyl, alkoxy, and haloalkyl groups, among others, which contribute to their pharmacological properties.
Furthermore, the patent claims cover pharmaceutical compositions containing these compounds along with suitable excipients. Additionally, methods for inhibiting ABHD12 activity in patients by administering effective amounts of the disclosed compounds are also included. Interestingly, some of the compounds are designed to not only inhibit ABHD12 activity but also stimulate the patient's immune system or initiate an immune response, showcasing potential dual therapeutic effects in treating certain conditions.
To know more about GlobalData’s detailed insights on H. Lundbeck, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.